Activation syndrome
Activation syndrome is a form of stimulation (sometimes suicidal) or agitation that has been observed in association with some psychoactive drugs.[1] A causative role has not been established.[2] Pfizer has denied that sertraline can cause such effects.[3][4]
Treatment
Serotonin reuptake inhibitors (SSRI) have been used in the induction of an "activation syndrome" (restlessness, labiality, etc.). The syndrome generally represents a state change that encourages suicidal tendencies in people under age 25 during the initial weeks of treatment.[5] SSRI-induced activation syndrome is well-accepted by clinicians. [6] Evidence reveal that jitteriness/anxiety syndrome predicts an improved prognosis (level D). Further, people with panic disorder with the syndrome may tolerate doses of tricyclic antidepressants without affecting outcome level D.[7] Activation syndrome resolves within hours of discontinuing the serotonergic agent and initiating care. However, drugs with half-lives may cause symptoms to persist. Monoamine oxidase inhibitors (MAOIs) carry the risk, and symptoms persist for several days.[8]
References
- ↑ http://www.breggin.com/recentregulatory.pbreggin.2006.pdf
- ↑ "www.accessdata.fda.gov" (PDF).
- ↑ http://www.healyprozac.com/AcademicStalking/Post%203%20-%20Pfizer%20letter%20re%20Healy.pdf
- ↑ http://www.ahrp.org/ethical/HealyResponseToPfizer.pdf
- ↑ "www.accessdata.fda.gov" (PDF).
- ↑ http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2867356/
- ↑ http://bjp.rcpsych.org/content/194/6/483.full
- ↑ http://www.uptodate.com/contents/serotonin-syndrome